UK, US drugmakers scrap 'futile' Alzheimer's treatment trial

June 12, 2018

British and American pharmaceutical giants AstraZeneca and Eli Lilly on Tuesday said they were ending a large clinical trial of a treatment for Alzheimer's that they had been developing jointly.

The decision to scrap the phase III clinical trial comes as a major setback in the race to find a cure for the disease, which is the most common form of dementia and affects millions of people around the world.

With a clinical trial failure rate of over 99 percent, there is still no licenced drug that slows Alzheimer's progression or cures it.

"We are saddened by this outcome as our researchers are working tirelessly to find a solution for the many people who are impacted by this devastating disease," Menelas Pangalos, executive vice president of AstraZeneca said in a statement.

"We won't give up on finding a solution for Alzheimer's patients," Daniel Skovronsky, president of Lilly Research Labs added.

The two firms announced a partnership to develop a new drug aimed at combatting Alzheimer's in 2014.

They were working on two treatments—one for patients with early Alzheimer's disease, the other for those with mild Alzheimer's disease dementia.

Both treatments used a so-called "inhibitor" targeting an enzyme called BACE.

Multiple blows

According to the statement, an independent data monitoring committee ruled that both the treatments "were not likely to meet their primary end-points upon completion and therefore should be stopped for futility".

The statement also said the discontinuation of the trials was not expected to have any financial impact on the firms' outlook for 2018.

Health systems in Western countries are struggling to deal with Alzheimer's as it is costly to treat sufferers of the incurable disease which leaves them increasingly reliant on assistance.

US pharmaceutical behemoth Pfizer announced in January it was pulling out of neuroscience research entirely.

Swiss giants Roche and Axovant, as well US firm Merck have all tried unsuccessfully to come up with the solution to Alzheimer's.

According to the World Health Organization, some 50 million people around the world have dementia, with Alzheimer's accounting for 60-70 percent of the cases.

As the world's population ages, the number of patients is expected to double by 2030 and to triple by 2050 if no cure is found.

The global cost of caring for sufferers was set to reach $1 trillion (850 billion euros) this year.

According to the Alzforum website, which gathers data on candidate drugs, fewer than 300 have made it to Phase II trials so far.

Only five have ever been approved to treat symptoms such as memory loss associated with Alzheimer's, a disease first identified more than 100 years ago.

"Although dementia mainly affects older people, it is not a normal part of ageing," the WHO says on its website.

"Dementia has a physical, psychological, social, and economic impact, not only on people with dementia, but also on their carers, families and society at large," it adds.

Explore further: Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

Related Stories

Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

May 22, 2018
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer's disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit ...

Merck halts trial of once 'promising' Alzheimer's drug

February 15, 2017
US pharmaceutical giant Merck announced it is halting a clinical trial on a drug once touted as a promising treatment for Alzheimer's disease, saying studies show it does not work.

New forecast shows 6 million with Alzheimer's disease, cognitive impairment

December 8, 2017
Using new methodology, scientists calculate that approximately 6 million American adults have Alzheimer's disease or mild cognitive impairment, which can sometimes be a precursor to the disease. The estimate, funded by the ...

Arthritis drugs linked to lower Alzheimer's risk

February 13, 2018
Scientists from the University of Southampton have teamed up with researchers from the University of Oxford to look at whether existing drugs for arthritis have any effect on a person's risk of developing dementia. By looking ...

Rocky start for Alzheimer's drug research in 2018

January 19, 2018
The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Recommended for you

New screening tool could help diagnose early cognitive decline in dementia from home

June 19, 2018
An international team of scientists have developed a new way to screen for age-related cognitive decline at home using a test which asks people to detect sounds and flashes on their laptop or phone.

Genes linked to Alzheimer's contribute to damage in different ways

June 12, 2018
Multiple genes are implicated in Alzheimer's disease. Some are linked to early-onset Alzheimer's, a condition that develops in one's 30s, 40s and 50s, while others are associated with the more common late-onset form of the ...

Researchers reverse cognitive impairments in mice with dementia

June 8, 2018
Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research. A lack of knowledge about cellular pathways critical to the development of dementia, however, has stood in the ...

As mystery deepens over the cause of Alzheimer's, researchers seek new answers

June 6, 2018
For more than 20 years, much of the leading research on Alzheimer's disease has been guided by the "amyloid hypothesis."

Research reveals how Tau aggregates can contribute to cell death in Alzheimer's disease

June 5, 2018
New evidence suggests a mechanism by which progressive accumulation of Tau protein in brain cells may lead to Alzheimer's disease. Scientists studied more than 600 human brains and fruit fly models of Alzheimer's disease ...

How does alcohol influence the development of Alzheimer's disease?

June 4, 2018
Research from the University of Illinois at Chicago has found that some of the genes affected by alcohol and inflammation are also implicated in processes that clear amyloid beta—the protein that forms globs of plaques ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.